Literature DB >> 15270644

TRICOM: enhanced vaccines as anticancer therapy.

Benjamin Levy1, Dennis Panicalli, John Marshall.   

Abstract

Renewed interest in immune therapies for the treatment of cancer has sparked a number of different immune stimulation approaches. These include antibody based, dendritic cell-based and vaccine-based therapies. The poxvirus-based vaccines incorporating a TRIad of COstimulatory Molecules (TRICOM) will be reviewed here. Through stimulation of cancer-specific T-cell responses, researchers have demonstrated interesting clinical efficacy in addition to the high safety profile in clinical trials.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15270644     DOI： 10.1586/14760584.3.4.397

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN： 1476-0584            Impact factor:   5.217


  3 in total

1.  Development of PROSTVAC immunotherapy in prostate cancer.

Authors:  Parminder Singh; Sumanta K Pal; Anitha Alex; Neeraj Agarwal
Journal:  Future Oncol       Date:  2015       Impact factor: 3.404

2.  A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer.

Authors:  R S DiPaola; M Plante; H Kaufman; D P Petrylak; R Israeli; E Lattime; K Manson; T Schuetz
Journal:  J Transl Med       Date:  2006-01-03       Impact factor: 5.531

Review 3.  Colorectal cancer vaccines: The current scenario and future prospects.

Authors:  Wenqing Jia; Tao Zhang; Haiyan Huang; Haoran Feng; Shaodong Wang; Zichao Guo; Zhiping Luo; Xiaopin Ji; Xi Cheng; Ren Zhao
Journal:  Front Immunol       Date:  2022-08-03       Impact factor: 8.786
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.